Blood pressure lowering oligopeptides

Abstract

The present invention describes a process to produce IPP from a protein source whereby the ratio of IPP and VPP produced from the protein is at least 5, preferably at least 10 and more preferably at least 20, which comprises the use of a proline specific endoprotease.

Description

field of invention [0001] The present invention relates to the production of IPP. Background of the invention [0002] Hypertension is a relatively common disease state in humans that represents a prevalent risk factor for cardiovascular disease, renal failure and stroke. The effectiveness of a large number of pharmaceutical products (e.g., calcium blockers (blockers), beta blockers, diuretics, alpha blockers, central alpha antagonists, angiotensin II antagonists, and ACE inhibitors), demonstrating high The underlying physiological mechanisms of blood pressure are multifaceted. [0003] The physiological mechanisms of hypertension, especially the renin-angiotensin mechanism, have attracted much scientific attention. In this mechanism, angiotensin is secreted by the liver and cleaved by the peptidase renin to produce the decapeptide angiotensin I, which is biologically inactive. As angiotensin I passes through the pulmonary capillaries, another peptidase called angiotensin...

AI Technical Summary

Problems solved by technology

The disadvantage of this method of fermentation is that lactic acid bacteria are living organisms for which it is difficult to control the type and amount of enzymes secreted

The production of ACE-inhibiting peptides is thus difficult to reproduce and it is not possible to generate an optimal set of enzymes to ensure maximum yield of the desired peptide

Furthermore, the relatively long fermentation times required, which together with low yields imply an unfavorable cost structure for bioactive peptides

In addition, fermented products are less suitable for direct addition to a.o. solid foods and can create severe sensory limitations

Images